Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry

Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer

Aaron Bartlone, Chief Operating Officer | Cybin

Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics

Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

Filament Health Is Issued Second Patent By United States Patent And Trademark Office And Reports Q1 Results

HAVN Life Announces Strategic Partnership with Non-Profit Coalition, TheraPsil

MindMed Reports First Quarter 2022 Financial Results and Business Highlights

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound

Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

Albert Labs Granted Health Canada Licence

MindMed Announces At-The-Market Offering

Mydecine Announces First Quarter 2022 Financial Results and Highlights